The future of the weight loss market might not revolve around GLP-1 drugs.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

GLP-1 supplement makers claim that their products work similarly to weight loss injections like Ozempic. Here's what experts ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...